The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.
G. Pfeiler
Honoraria - AstraZeneca; Novartis
R. Königsberg
No relevant relationships to disclose
B. Mlineritsch
No relevant relationships to disclose
H. Stoger
No relevant relationships to disclose
C. F. Singer
Honoraria - AstraZeneca; Novartis
S. Poestlberger
Honoraria - AstraZeneca; Novartis; Roche
G. G. Steger
Honoraria - AstraZeneca; Novartis
M. Seifert
Honoraria - AstraZeneca; Novartis
P. C. Dubsky
Honoraria - AstraZeneca; Novartis
R. Jakesz
Consultant or Advisory Role - AstraZeneca; Roche; Sanofi
Honoraria - AstraZeneca; Roche; Sanofi
H. Samonigg
Honoraria - AstraZeneca; Merck; Roche
V. Bjelic-Radisic
No relevant relationships to disclose
R. Greil
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca; Novartis
C. Marth
No relevant relationships to disclose
C. Fesl
No relevant relationships to disclose
M. Gnant
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Honoraria - AstraZeneca; Novartis; Pfizer; Roche; Schering-Plough